UK

Adults with obesity and a BMI of 30 kg/m² or higher can now use Wegovy at a 7.2mg dose level, which requires three consecutive 2.4mg doses instead of a single injection.

With this latest authorisation, individuals now have access to a long-acting option for prevention rather than daily pill-based regimens.

The therapy is indicated for patients aged 12 years and older with severe asthma characterized by an eosinophilic phenotype.

This oral formulation offers a more convenient delivery method compared to intravenous treatments.